omeprazole has been researched along with bupropion in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (10.00) | 29.6817 |
2010's | 16 (80.00) | 24.3611 |
2020's | 2 (10.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Dai, R; Liu, Y; She, M; Wu, Z | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Kailajärvi, M; Lammintausta, R; Lehtinen, T; Pelkonen, O; Scheinin, M; Stjernschantz, C; Tapanainen, P; Turpeinen, M; Uusitalo, J; Vuorinen, J | 1 |
Buchbjerg, JK; Chen, G; Højer, AM; Lee, R; Serenko, M; Zhao, Z | 1 |
Chen, M; Chen, X; Han, A; Lin, G; Ma, J; Wang, X; Wen, C; Yang, X | 1 |
Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Staub, C; Walder, B | 1 |
Bosilkovska, M; Daali, Y; Dayer, P; Déglon, J; Desmeules, JA; Rebsamen, M; Samer, CF; Staub, C; Walder, B | 1 |
Chen, WH; Chen, ZB; Hu, LF; Li, D; Lin, FY; Yu, XG; Zhi, AY | 1 |
Lin, C; Lin, G; Ma, J; Wang, S; Wang, X; Zhang, M; Zhang, Q; Zhou, Y | 1 |
Lin, K; Lin, Y; Liu, Z; Wen, C; Yang, S; Zhang, Q; Zheng, Y | 1 |
Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B | 1 |
Burmistrova, OA; Poloznikov, AA; Sakharov, DA; Shkurnikov, MY; Zakhariants, AA | 1 |
Chiasson, JL; Grangeon, A; Gravel, S; Michaud, V; Turgeon, J | 1 |
Andersson, TB; Artursson, P; Christensen, H; Krogstad, V; Matsson, P; Urdzik, J; Wegler, C | 1 |
Brantley, SJ; Dai, X; Goulet, MT; Hard, ML; Hitron, M; Karol, MD; McLaughlin, CF | 1 |
1 review(s) available for omeprazole and bupropion
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for omeprazole and bupropion
Article | Year |
---|---|
Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.
Topics: Adolescent; Adult; Antidepressive Agents; Antifungal Agents; Bupropion; Cohort Studies; Contraceptives, Oral, Hormonal; Cross-Over Studies; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Fluconazole; Humans; Ketoconazole; Male; Middle Aged; Omeprazole; Piperazines; Rifampin; Single-Blind Method; Sulfides; Vortioxetine; Young Adult | 2013 |
Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Topics: Adolescent; Adult; Bupropion; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Drug Interactions; Female; Flurbiprofen; Genotyping Techniques; Humans; Male; Midazolam; Omeprazole; Phenotype; Terfenadine; Young Adult | 2016 |
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Bupropion; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Flurbiprofen; Gene Expression Regulation; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Naphthoquinones; Neoplasm Proteins; Omeprazole; Rosuvastatin Calcium; Young Adult | 2021 |
16 other study(ies) available for omeprazole and bupropion
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Topics: Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Molecular Structure; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.
Topics: Aged; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Area Under Curve; Bupropion; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Half-Life; Hepatocytes; Humans; Microsomes, Liver; Middle Aged; Omeprazole; Tamoxifen; Warfarin | 2013 |
The effects of H2S on the activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in vivo in rat.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Activation; Enzyme Inhibitors; Half-Life; Hydrogen Sulfide; Male; Mass Spectrometry; Midazolam; Omeprazole; Rats; Rats, Sprague-Dawley; Tolbutamide | 2013 |
Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Flurbiprofen; Half-Life; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2014 |
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Capsules; Carbonated Beverages; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Coffee; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Enzyme Inhibitors; Feasibility Studies; Flurbiprofen; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenotype; Pilot Projects; Predictive Value of Tests; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2014 |
Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat.
Topics: Animals; Bupropion; Cytochrome P-450 Enzyme System; Doxorubicin; Male; Nephrotic Syndrome; Omeprazole; Phenacetin; Rats, Sprague-Dawley; Tolbutamide | 2014 |
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
Topics: Adjuvants, Anesthesia; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Hypoglycemic Agents; Limit of Detection; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenacetin; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tolbutamide | 2015 |
Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.
Topics: Administration, Oral; Animals; Bupropion; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochromes; Drug Interactions; Edema; Enzyme Induction; Histone Deacetylase Inhibitors; Hydroxamic Acids; Liver; Male; Metoprolol; Omeprazole; Phenacetin; Rats, Sprague-Dawley; Substrate Specificity; Tandem Mass Spectrometry; Tolbutamide; Vorinostat | 2015 |
Development of a Specific Substrate-Inhibitor Panel (Liver-on-a-Chip) for Evaluation of Cytochrome P450 Activity.
Topics: Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Humans; Ketoconazole; Lab-On-A-Chip Devices; Liver; Mass Spectrometry; Mephenytoin; Microsomes, Liver; Omeprazole; Phencyclidine; Substrate Specificity; Sulfaphenazole; Testosterone; Tolbutamide | 2016 |
Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Bupropion; Caffeine; Case-Control Studies; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diabetes Mellitus, Type 2; Female; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Tolbutamide; Tumor Necrosis Factor-alpha | 2019 |
Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.
Topics: Bupropion; Cytochrome P-450 Enzyme System; Diclofenac; Drug Evaluation, Preclinical; Ethanolamines; Hepatobiliary Elimination; Hepatocytes; Humans; Liver; Microsomes, Liver; Midazolam; Omeprazole; Proteome; Proteomics | 2021 |